219 related articles for article (PubMed ID: 10553808)
1. Intracavernosal therapy for erectile failure--impact of treatment and reasons for drop-out and dissatisfaction.
Purvis K; Egdetveit I; Christiansen E
Int J Impot Res; 1999 Oct; 11(5):287-99. PubMed ID: 10553808
[TBL] [Abstract][Full Text] [Related]
2. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
Purvis K; Brekke I; Christiansen E
Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
[TBL] [Abstract][Full Text] [Related]
3. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
Kunelius P; Lukkarinen O
Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
[TBL] [Abstract][Full Text] [Related]
4. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy.
Sexton WJ; Benedict JF; Jarow JP
J Urol; 1998 Mar; 159(3):811-5. PubMed ID: 9474156
[TBL] [Abstract][Full Text] [Related]
5. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
Sung HH; Ahn JS; Kim JJ; Choo SH; Han DH; Lee SW
Andrology; 2014 Jan; 2(1):45-50. PubMed ID: 24194017
[TBL] [Abstract][Full Text] [Related]
6. Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction.
Casabé A; Bechara A; Cheliz G; Romano S; Rey H; Fredotovich N
Int J Impot Res; 1998 Mar; 10(1):5-9. PubMed ID: 9542684
[TBL] [Abstract][Full Text] [Related]
7. Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction.
Soderdahl DW; Thrasher JB; Hansberry KL
Br J Urol; 1997 Jun; 79(6):952-7. PubMed ID: 9202565
[TBL] [Abstract][Full Text] [Related]
8. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
Engel JD; McVary KT
Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
[TBL] [Abstract][Full Text] [Related]
9. Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic.
Armstrong DK; Convery A; Dinsmore WW
Int J STD AIDS; 1993; 4(4):214-6. PubMed ID: 8399501
[TBL] [Abstract][Full Text] [Related]
10. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment.
Brock G; Tu LM; Linet OI
Urology; 2001 Mar; 57(3):536-41. PubMed ID: 11248634
[TBL] [Abstract][Full Text] [Related]
11. Patient satisfaction with pharmacologic erection program.
Hollander JB; Gonzalez J; Norman T
Urology; 1992 May; 39(5):439-41. PubMed ID: 1580034
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
Linet OI; Ogrinc FG
N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
[TBL] [Abstract][Full Text] [Related]
13. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
Vardi Y; Lidgi S; Moskovitz B; Levin RD
Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
[TBL] [Abstract][Full Text] [Related]
14. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.
Kiely EA; Bloom SR; Williams G
Br J Urol; 1989 Aug; 64(2):191-4. PubMed ID: 2765789
[TBL] [Abstract][Full Text] [Related]
15. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
[TBL] [Abstract][Full Text] [Related]
16. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
Asuar Aydillo S
Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
[No Abstract] [Full Text] [Related]
17. Therapeutic roles of intracavernosal papaverine.
Goldstein I; Payton T; Padma-Nathan H
Cardiovasc Intervent Radiol; 1988 Aug; 11(4):237-9. PubMed ID: 3147138
[TBL] [Abstract][Full Text] [Related]
18. Intracavernous Alprostadil Alfadex--an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study.
Porst H; Buvat J; Meuleman E; Michal V; Wagner G
Int J Impot Res; 1998 Dec; 10(4):225-31. PubMed ID: 9884918
[TBL] [Abstract][Full Text] [Related]
19. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction.
Chao R; Clowers DE
Arch Phys Med Rehabil; 1994 Mar; 75(3):276-8. PubMed ID: 8129578
[TBL] [Abstract][Full Text] [Related]
20. Intracavernosal injection of pharmacological agents in the diagnosis and treatment of impotence.
Siraj QH; Akhtar MA
J Pak Med Assoc; 1989 Jul; 39(7):172-6. PubMed ID: 2504962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
